Inogen (INGN) Stock Price, News & Analysis

Company Overview

Inogen, Inc. is a medical technology company specializing in the design, manufacture and distribution of oxygen therapy solutions for patients with chronic respiratory conditions. The company’s primary offerings include a family of portable oxygen concentrators (POCs) and home oxygen concentrators (HOCs), engineered to provide continuous and pulse flow oxygen delivery. Inogen’s products are designed to enhance patient mobility, allowing users to maintain active lifestyles while receiving prescribed oxygen therapy.

Founded in 2001 and headquartered in Goleta, California, Inogen has established a global footprint through direct sales, rental channels and partnerships with home healthcare providers. The company operates manufacturing facilities in California and distributes its devices across North America, Europe, and selected markets in Asia and Latin America. Inogen’s portable concentrators, known for their lightweight design and long-lasting battery life, have become a standard of care in many home and outpatient settings.

Under the leadership of its executive team, Inogen continues to invest in research and development to advance portable oxygen technology. The company’s interdisciplinary R&D group focuses on improving device efficiency, reducing overall weight, extending battery performance and integrating smart monitoring features. Inogen also collaborates with clinicians, therapists and patient advocacy organizations to ensure its products address real-world patient needs and regulatory requirements.

Looking ahead, Inogen remains committed to broadening its product portfolio and expanding patient access to oxygen therapy. The company is exploring new models and accessory solutions that support telehealth integration, remote patient monitoring and customizable oxygen delivery profiles. Through ongoing innovation and a dedication to quality standards, Inogen aims to deliver safe, reliable and user-friendly oxygen therapy for patients worldwide.

Key Stats

• Today's Range: $6.48 to $6.60
• 50-Day Range: $5.75 to $7.50
• 52-Week Range: $5.70 to $13.33
• Volume: 18,758 shs
• Average Volume: 242,810 shs
• Market Capitalization: $174.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Moderate Buy

Inogen Stock Analysis - MarketRank™

Inogen scored higher than 84% of companies evaluated by MarketBeat, and ranked 145th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Inogen has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Inogen has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Inogen are expected to grow in the coming year, from ($1.73) to ($1.48) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Inogen is -5.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Inogen is -5.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Inogen has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.81% of the float of Inogen has been sold short.

Short Interest Ratio / Days to Cover

Inogen has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in Inogen has recently decreased by 6.48%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Inogen does not currently pay a dividend.

Dividend Growth

Inogen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -1.12

Percentage of Shares Shorted

3.81% of the float of Inogen has been sold short.

Short Interest Ratio / Days to Cover

Inogen has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in Inogen has recently decreased by 6.48%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: 0.47

News Sentiment

Inogen has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.97 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Inogen this week, compared to 3 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Inogen insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.46% of the stock of Inogen is held by insiders.

Percentage Held by Institutions

89.94% of the stock of Inogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

INGN Stock Analysis - Frequently Asked Questions

How have INGN shares performed this year?

Inogen's stock was trading at $9.17 at the beginning of the year. Since then, INGN shares have decreased by 28.7% and is now trading at $6.54.

How were Inogen's earnings last quarter?

Inogen, Inc (NASDAQ:INGN) issued its earnings results on Wednesday, May, 7th. The medical technology company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.27. The medical technology company earned $82.28 million during the quarter, compared to analysts' expectations of $79.57 million. Inogen had a negative trailing twelve-month return on equity of 14.76% and a negative net margin of 8.08%.
Read the conference call transcript.

Who are Inogen's major shareholders?

Inogen's top institutional investors include Wealth Enhancement Advisory Services LLC (0.07%).
View institutional ownership trends.

How do I buy shares of Inogen?

Shares of INGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Inogen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Inogen investors own include American Water Works (AWK), Waste Connections (WCN), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), Voyager Therapeutics (VYGR) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/16/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:INGN
• CIK: 1294133
• Web: www.inogen.com
• Phone: (805) 562-0500
• Fax: N/A
• Employees: 1,030
• Year Founded: 2001

Price Target and Rating

• Average Price Target for Inogen: $11.00
• High Price Target: $14.00
• Low Price Target: $7.00
• Potential Upside/Downside: +67.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.89 million
• Net Margins: -8.08%
• Pretax Margin: -8.24%
• Return on Equity: -14.76%
• Return on Assets: -9.01%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.07
• Quick Ratio: 2.67

Sales & Book Value

• Annual Sales: $335.70 million
• Price / Sales: 0.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.30 per share
• Price / Book: 0.90

Miscellaneous

• Outstanding Shares: 26,890,000
• Free Float: 26,494,000
• Market Cap: $176.13 million
• Optionable: Optionable
• Beta: 1.66